Bailey CJ, et al. - Given that dapagliflozin is correlated with greater declines in HbA1c and weight than saxagliptin in management of T2DM, researchers compared the durability of these impacts over short- and long-term follow-up in patients with T2DM who were inadequately controlled with metformin (≥ 1500 mg/day) and who were receiving either dapagliflozin (10 mg/day) or saxagliptin (5 mg/day). Using the slope of the change in HbA1c from baseline-over-time regression line (coefficient of failure [CoF]), failure of glycaemiccontrol was evaluated. According to the present post hoc analyses, dapagliflozin was linked to greater durability of glycaemic control than saxagliptin over 18–24 and 20–102 weeks in T2DM patients who were inadequately controlled with metformin.